3 min read

Remdesivir Reduces Risk of Hospitalization When Given to Patients Early

Zachary Stieber 

The Epoch Times - Zachary Stieber - September 22, 2021

The antiviral Remdesivir treatment reduced the risk of hospitalization among COVID-19 patients when administered soon after they were diagnosed, according to a new study. Researchers found that Remdesivir cut the risk of hospitalization by 87 percent compared to a placebo that half of the study participants received.

A total of 562 patients, all deemed at high-risk from COVID-19, were enrolled in the trial.

Gilead Sciences, which developed Remdesivir and conducted the Phase 3 randomized, double-blind trial, stopped trial enrollment in April because the company struggled to find enough participants. But it continued to follow those who had enrolled, half of whom were given a placebo.

Participants received the antiviral through IV on three consecutive days as nonhospitalized patients. That’s impractical for people outside of hospitals, some experts say.

Chandy John Lab, professor of pediatrics at the Indiana University School of Medicine, wrote in a social media post that monoclonal antibodies are designed to prevent hospitalization and only require a single dose, making them a preferred treatment option over Remdesivir. Both cost thousands of dollars.

Remdesivir, also known as Veklury, is already approved by U.S. drug regulators for use against COVID-19, but the approval is only for patients who are already hospitalized, 12 or older, and weigh at least 88 pounds. Gilead hopes that its drug can help prevent hospitalizations, in line with the monoclonals, which are in such high demand that the Biden administration has rationed them.

The new study also showed a similar safety profile to the placebo and no deaths occurred in either group by the primary endpoint at day 28, though one person who was given the placebo died on day 59, Gilead said.

“These latest data show Remdesivir’s potential to help high-risk patients recover before they get sicker and stay out of the hospital altogether,” Dr. Robert Gottlieb, a cardiologist at Baylor University Medical Center and Baylor Scott & White Research Institute, said in a statement released by the company.

Gilead plans to share its findings with the Food and Drug Administration.

Remdesivir has been touted by top U.S. officials in the past, including Dr. Anthony Fauci, and early studies indicated it was effective in reducing hospitalization when given to COVID-19 patients. But other research has suggested that it has no benefit, including a trial across 48 sites in Europe.

“No clinical benefit was observed from the use of Remdesivir in patients who were admitted to hospital for COVID-19, were symptomatic for more than 7 days, and required oxygen support,” researchers wrote in The Lancet last week.

Some studies have also linked the drug to kidney disease and other severe side effects.

Regulators said in their approval letter that the known and potential benefits of Veklury outweigh the known and potential risks of the drug.

Gilead plans to present the full trial results this week at IDWeek, a medical conference.

Editor’s Note: This article has been updated with details about side effects linked to Remdesivir.

Follow Zachary Stieber covers U.S. news, including politics and court cases. He started at The Epoch Times as a New York City metro reporter.


Copy & Paste the link above for Yandex translation to Norwegian.

WHO and WHAT is behind it all ? : >

The bottom line is for the people to regain their original, moral principles, which have intentionally been watered out over the past generations by our press, TV, and other media owned by the Illuminati/Bilderberger Group, corrupting our morals by making misbehavior acceptable to our society. Only in this way shall we conquer this oncoming wave of evil.




All articles contained in Human-Synthesis are freely available and collected from the Internet. The interpretation of the contents is left to the readers and do not necessarily represent the views of the Administrator. Disclaimer: The contents of this article are of sole responsibility of the author(s). Human-Synthesis will not be responsible for any inaccurate or incorrect statement in this article. Human-Synthesis grants permission to cross-post original Human-Synthesis articles on community internet sites as long as the text & title are not modified